Royalty Pharma plc (RPRX)

Our PAST TOP PICK with RPRX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $43) to $47 at this time.

Our PAST TOP PICK with RPRX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $39) to $43 at this time.  

Our PAST TOP PICK with RPRX has achieved its target at $44.  To remain disciplined, we recommend covering half the position at this time and maintaining the stop at $39.  

Our PAST TOP PICK with RPRX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $34.50) to $39.00 at this time.  

We again reiterate RPRX, holder of royalties in over 35 pharmaceutical products as a TOP PICK.  Earnings will be reported early in November and analysts expect a 6% increase in earnings on the back of a 9% increase in revenues.  It trades at 16x earnings, 2.5x book and supports a 15% ROE.  Cash reserves are prudently being used to aggressively buy back shares and retire debt, but with $2.5 billion in free cash flow this is not a concern.  We continue to recommend a stop at $34.50, looking to achieve $44 -- upside potential of 18%.  Yield 2.3%

RPRX is the largest buyer of biopharma royalties in the world.  They draw their value from providing innovative financing to pharma partners, while sharing in the top line revenue of the new products developed.  Deloitte just released a study highlighting the importance of royalties in new pharma development -- and RPRX leads the way.  It trades at 8x earnings, 2.2x book and supports a 25% ROE.  Quarterly cashflow is cautiously being used to aggressively buy back shares.  We recommend maintaining a stop at $34.50, looking to achieve $45 -- upside potential of 25%.  Yield 2.4%

Our PAST TOP PICK with RPRX is progressing well.  To remain disciplined, we recommend trailing up the stop (from $29.00) to $34.50 at this time.

Following recently reported earnings, we reiterate RPRX as a TOP PICK.  Their drug portfolio royalty receipts are showing steady growth - up another 12% this year.  Management sees good progress on new projects, including a recent announcement of a partnership with Biogen.  It trades at 17x earnings, 2.1x book, and supports a 12% ROE.  We continue to recommend a stop at $29, looking to achieve $40 -- upside potential of 21%.  Yield 2.5%

We reiterate RPRX as a TOP PICK.  This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development.  It trades at 17x earnings, 2.1x book and supports a 12% ROE.  We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%.  Yield 2.6%

We reiterate RPRX as a TOP PICK.  The company is the largest holder of pharma based royalties, providing late stage funding for forward cash royalties.  The company just monetized a recent investment that netted $230 million -- a 76% return on investment -- allowing for a pay down in debt, continuation in share buy backs, and further product development.  The company trades at 8x earnings, 1.8x book and supports a ROE of 24%.  We recommend trailing up the stop (from $22) to $26, looking to achieve $40 -- upside potential of 25%.  Yield 2.6% 

RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties.  It pays a good dividend, backed by a payout ratio under 33% of cash flow.  It trades at 10x earnings, under 2x book and supports a 17% ROE.  Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%.  Yield 3.2%